Farshad Guirakhoo

Dr. Farshad Guirakhoo was named in 2014 as no. 22 in the list of the 50 Most Influential People in Vaccines. His most recent assignment was the Chief Technology Officer (CTO) of Vaxess Technologies, Inc., an innovative life sciences company developing a novel vaccine stabilization technology.

Dr. Guirakhoo has broad experience in the application of genetics, gene expression technologies, and molecular virology for the constructions and productions of recombinant proteins, human antibodies, and attenuated viral vectored vaccines for the prevention and treatment of infectious diseases. Dr. Guirakhoo is the author of over 80 peer-reviewed publications, including book chapters, and holds multiple patents.

Dr. Guirakhoo received his Ph.D. in Virology from the University of Vienna, Austria, and holds an M.Sc. in Genetics, and a B.Sc. in Biology. He has been awarded the National Research Council Post-Doctorate Award and studied at the National Centers for Disease Control (CDC), Division of Vector-Borne Infectious Diseases (DVBID), in Fort Collins, CO.